oncopatОнкопатологияONCOPATHOLOGY2618-70193034-353410.17650/2618-7019-2023-6-1-2-26-32oncopat-72Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESПятое издание классификации Всемирной организации здравоохранения почечно-клеточных опухолей. Обзор изменнийThe 5th edition of the World Health Organization classification of renal cell tumors. Overview of changesГорбаньН. А.GorbanN.  A.

121359 Москва, ул. Маршала Тимошенко, 15

Nina Andreevna Gorban15 Marshala Timoshenko St., Moscow 121359

perovanina@mail.ruМихайленкоД. С.MikhaylenkoD.  S.

115522 Москва, ул. Москворечье, 1

1 Moskvorechye St., Moscow 115522

ФГБУ «Центральная клиническая больница с поликлиникой» Управления делами Президента Российской ФедерацииРоссияCentral Clinical Hospital with Polyclinic, Administration of the President of the Russian FederationRussian FederationФГБНУ «Медико-генетический научный центр им. акад. Н. П. Бочкова»РоссияN.P. Bochkov Research Center for Medical GeneticsRussian Federation20233009202661-22632Copyright © Горбань Н.А., Михайленко Д.С., 20262026Горбань Н.А., Михайленко Д.С.Gorban N.A., Mikhaylenko D.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://oncopat.elpub.ru/jour/article/view/72

Представления об опухолях почек за последние 20 лет претерпели большие изменения. В статье приведен анализ новой классификации опухолей почек и ее реформирования. Пятое издание классификации Всемирной организации здравоохранения опухолей мочевыделительной системы и мужских половых органов отражает развитие концепции, заложенной в предыдущих изданиях. Преобразована и усовершенствована концептуальная организация классификации опухолей почек, включены новые типы.

The understanding of kidney tumors has undergone great changes over the past 20 years. The article provides an anal‑ ysis of the new classification of kidney tumors and its reform. The 5th edition of the World Health Organization classifi‑ cation of tumors of the urinary system and male genital organs reflects the development of the concept laid down in previous editions. The conceptual organization of the classification of renal tumors has been transformed and improved, and new types have been included.

опухоль почкипочечно-клеточный рак5-е издание классификации Всемирной организации здравоохраненияkidney tumorrenal cell carcinoma5th edition of the World Health Organization classificationРабота выполнена без спонсорской поддержкиThe work was performed without external funding.ReferencesKovacs G., Akhtar M., Beckwith B., et al. The Heidelberg classification of renal cell tumours. J Pathol. 1997;183:131–133.Kovacs G., Akhtar M., Beckwith B., et al. The Heidelberg classification of renal cell tumours. J Pathol. 1997;183:131–133.Fleming S. Genetics of kidney tumours. Forum (Genova). 1998;8(2):176–184.Fleming S. Genetics of kidney tumours. Forum (Genova). 1998;8(2):176–184.Eble J.N. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon; Oxford: IARC Press; Oxford University Press; 2004.Eble J.N. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon; Oxford: IARC Press; Oxford University Press; 2004.Moch H., Humphrey P.A., Ulbright T.M., Reuter V.E. WHO Classification of Tumours of the Urinary System and Male Genital Organs. 4th ed. Lyon: IARC Press; 2016.Moch H., Humphrey P.A., Ulbright T.M., Reuter V.E. WHO Classification of Tumours of the Urinary System and Male Genital Organs. 4th ed. Lyon: IARC Press; 2016.WHO Classification of Tumours of the Urinary System and Male Genital Organs. 5th ed. Lyon: International Agency for Research on Cancer; 2022.WHO Classification of Tumours of the Urinary System and Male Genital Organs. 5th ed. Lyon: International Agency for Research on Cancer; 2022.Delahunt B., Cheville J.C., Martignoni G., et al. Members of the ISUP Renal Tumor Panel. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013;37(10):1490–1504. DOI: 10.1097/PAS.0b013e318299f0fb.Delahunt B., Cheville J.C., Martignoni G., et al. Members of the ISUP Renal Tumor Panel. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013;37(10):1490–1504. DOI: 10.1097/PAS.0b013e318299f0fb.Tretiakova M., Mehta V., Kocherginsky M., et al. Predominantly cystic clear cell renal cell carcinoma and multilocular cystic renal neoplasm of low malignant potential form a low-grade spectrum. Virchows Arch. 2018;473(1):85–93. DOI: 10.1007/s00428-018-2371-8.Tretiakova M., Mehta V., Kocherginsky M., et al. Predominantly cystic clear cell renal cell carcinoma and multilocular cystic renal neoplasm of low malignant potential form a low-grade spectrum. Virchows Arch. 2018;473(1):85–93. DOI: 10.1007/s00428-018-2371-8.Williamson S.R., Halat S., Eble J.N., et al. Multilocular cystic renal cell carcinoma: similarities and differences in immunoprofile compared with clear cell renal cell carcinoma. Am J Surg Pathol. 2012;36(10):1425–1433. DOI: 10.1097/PAS.0b013e31825b37f0.Williamson S.R., Halat S., Eble J.N., et al. Multilocular cystic renal cell carcinoma: similarities and differences in immunoprofile compared with clear cell renal cell carcinoma. Am J Surg Pathol. 2012;36(10):1425–1433. DOI: 10.1097/PAS.0b013e31825b37f0.Westerman M.E., Cheville J.C., Lohse C.M., et al. Long-term outcomes of patients with low grade cystic renal epithelial neoplasms. Urology. 2019;133:145–150. DOI: 10.1016/j.urology.2019.07.017.Westerman M.E., Cheville J.C., Lohse C.M., et al. Long-term outcomes of patients with low grade cystic renal epithelial neoplasms. Urology. 2019;133:145–150. DOI: 10.1016/j.urology.2019.07.017.Skenderi F., Ulamec M., Vanecek T., et al. Warthin-like papillary renal cell carcinoma: clinicopathologic, morphologic, immunohistochemical and molecular genetic analysis of 11 cases. Ann Diagn Pathol. 2017;27:48–56. DOI: 10.1016/j.anndiagpath.2017.01.005.Skenderi F., Ulamec M., Vanecek T., et al. Warthin-like papillary renal cell carcinoma: clinicopathologic, morphologic, immunohistochemical and molecular genetic analysis of 11 cases. Ann Diagn Pathol. 2017;27:48–56. DOI: 10.1016/j.anndiagpath.2017.01.005.Kunju L.P., Wojno K., Wolf J.S. Jr, et al. Papillary renal cell carcinoma with oncocytic cells and nonoverlapping low grade nuclei: expanding the morphologic spectrum with emphasis on clinicopathologic, immunohistochemical and molecular features. Hum Pathol. 2008;39(1):96–101. DOI: 10.1016/j.humpath.2007.05.016.Kunju L.P., Wojno K., Wolf J.S. Jr, et al. Papillary renal cell carcinoma with oncocytic cells and nonoverlapping low grade nuclei: expanding the morphologic spectrum with emphasis on clinicopathologic, immunohistochemical and molecular features. Hum Pathol. 2008;39(1):96–101. DOI: 10.1016/j.humpath.2007.05.016.Al-Obaidy K.I., Eble J.N., Nassiri M., et al. Recurrent KRAS mutations in papillary renal neoplasm with reverse polarity. Mod Pathol. 2020;33(6):1157–1164. DOI: 10.1038/s41379-019-0362-1.Al-Obaidy K.I., Eble J.N., Nassiri M., et al. Recurrent KRAS mutations in papillary renal neoplasm with reverse polarity. Mod Pathol. 2020;33(6):1157–1164. DOI: 10.1038/s41379-019-0362-1.Chen Y.B., Mirsadraei L., Jayakumaran G., et al. Somatic mutations of TSC2 or MTOR characterize a morphologically distinct subset of sporadic renal cell carcinoma with eosinophilic and vacuolated cytoplasm. Am J Surg Pathol. 2019;43(1):121–131. DOI: 10.1097/PAS.0000000000001170.Chen Y.B., Mirsadraei L., Jayakumaran G., et al. Somatic mutations of TSC2 or MTOR characterize a morphologically distinct subset of sporadic renal cell carcinoma with eosinophilic and vacuolated cytoplasm. Am J Surg Pathol. 2019;43(1):121–131. DOI: 10.1097/PAS.0000000000001170.Tjota M., Chen H., Parilla M., et al. Eosinophilic renal cell tumors with TSC and MTOR gene mutations are morphologically and immunohistochemically heterogeneous: clinicopathologic and molecular study. Am J Surg Pathol. 2020;44(7):943–954. DOI: 10.1097/PAS.0000000000001457.Tjota M., Chen H., Parilla M., et al. Eosinophilic renal cell tumors with TSC and MTOR gene mutations are morphologically and immunohistochemically heterogeneous: clinicopathologic and molecular study. Am J Surg Pathol. 2020;44(7):943–954. DOI: 10.1097/PAS.0000000000001457.Trpkov K., Williamson S.R., Gao Y., et al. Low-grade oncocytic tumour of kidney (CD117-negative, cytokeratin 7-positive): a distinct entity? Histopathology. 2019;75(2):174–184. DOI: 10.1111/his.13865.Trpkov K., Williamson S.R., Gao Y., et al. Low-grade oncocytic tumour of kidney (CD117-negative, cytokeratin 7-positive): a distinct entity? Histopathology. 2019;75(2):174–184. DOI: 10.1111/his.13865.Siadat F., Trpkov K. ESC, ALK, HOT and LOT: three letter acronyms of emerging renal entities knocking on the door of the WHO Classification. Cancers (Basel). 2020;12(1):168. DOI: 10.3390/cancers12010168.Siadat F., Trpkov K. ESC, ALK, HOT and LOT: three letter acronyms of emerging renal entities knocking on the door of the WHO Classification. Cancers (Basel). 2020;12(1):168. DOI: 10.3390/cancers12010168.Guo Q., Liu N., Wang F., et al. Characterization of a distinct low-grade oncocytic renal tumor (CD117-negative and cytokeratin 7-positive) based on a tertiary oncology center experience: the new evidence from China. Virchows Arch. 2021;478(3):449–458. DOI: 10.1007/s00428-020-02927-0.Guo Q., Liu N., Wang F., et al. Characterization of a distinct low-grade oncocytic renal tumor (CD117-negative and cytokeratin 7-positive) based on a tertiary oncology center experience: the new evidence from China. Virchows Arch. 2021;478(3):449–458. DOI: 10.1007/s00428-020-02927-0.Dhakal H.P., McKenney J.K., Khor L.Y., et al. Renal neoplasms with overlapping features of clear cell renal cell carcinoma and clear cell papillary renal cell carcinoma: a clinicopathologic study of 37 cases from a single institution. Am J Surg Pathol. 2016;40(2):141–154. DOI: 10.1097/PAS.0000000000000583.Dhakal H.P., McKenney J.K., Khor L.Y., et al. Renal neoplasms with overlapping features of clear cell renal cell carcinoma and clear cell papillary renal cell carcinoma: a clinicopathologic study of 37 cases from a single institution. Am J Surg Pathol. 2016;40(2):141–154. DOI: 10.1097/PAS.0000000000000583.Williamson S.R., Gupta N.S., Eble J.N., et al. Clear cell renal cell carcinoma with borderline features of clear cell papillary renal cell carcinoma: combined morphologic, immunohistochemical, and cytogenetic analysis. Am J Surg Pathol. 2015;39(11):1502–1510. DOI: 10.1097/PAS.0000000000000514.Williamson S.R., Gupta N.S., Eble J.N., et al. Clear cell renal cell carcinoma with borderline features of clear cell papillary renal cell carcinoma: combined morphologic, immunohistochemical, and cytogenetic analysis. Am J Surg Pathol. 2015;39(11):1502–1510. DOI: 10.1097/PAS.0000000000000514.Wang K., Zarzour J., Rais-Bahrami S., Gordetsky J. Clear cell papillary renal cell carcinoma: new clinical and imaging characteristics. Urology. 2017;103:136–141. DOI: 10.1016/j.urology.2016.12.002.Wang K., Zarzour J., Rais-Bahrami S., Gordetsky J. Clear cell papillary renal cell carcinoma: new clinical and imaging characteristics. Urology. 2017;103:136–141. DOI: 10.1016/j.urology.2016.12.002.Guo J., Tretiakova M.S., Troxell M.L., et al. Tuberous sclerosis-associated renal cell carcinoma: a clinicopathologic study of 57 separate carcinomas in 18 patients. Am J Surg Pathol. 2014;38(11):1457–1467. DOI: 10.1097/PAS.0000000000000248.Guo J., Tretiakova M.S., Troxell M.L., et al. Tuberous sclerosis-associated renal cell carcinoma: a clinicopathologic study of 57 separate carcinomas in 18 patients. Am J Surg Pathol. 2014;38(11):1457–1467. DOI: 10.1097/PAS.0000000000000248.Schreiner A., Daneshmand S., Bayne A., et al. Distinctive morphology of renal cell carcinomas in tuberous sclerosis. Int J Surg Pathol. 2010;18(5):409–418. DOI: 10.1177/1066896909333510.Schreiner A., Daneshmand S., Bayne A., et al. Distinctive morphology of renal cell carcinomas in tuberous sclerosis. Int J Surg Pathol. 2010;18(5):409–418. DOI: 10.1177/1066896909333510.Trpkov K., Hes O., Bonert M., et al. Eosinophilic, solid, and cystic renal cell carcinoma: clinicopathologic study of 16 unique, sporadic neoplasms occurring in women. Am J Surg Pathol. 2016;40(1):60–71. DOI: 10.1097/PAS.0000000000000508.Trpkov K., Hes O., Bonert M., et al. Eosinophilic, solid, and cystic renal cell carcinoma: clinicopathologic study of 16 unique, sporadic neoplasms occurring in women. Am J Surg Pathol. 2016;40(1):60–71. DOI: 10.1097/PAS.0000000000000508.Palsgrove D.N., Li Y., Pratilas C.A., et al. Eosinophilic solid and cystic (ESC) renal cell carcinomas harbor TSC mutations: molecular analysis supports an expanding clinicopathologic spectrum. Am J Surg Pathol. 2018;42(9):1166–1181. DOI: 10.1097/PAS.0000000000001111.Palsgrove D.N., Li Y., Pratilas C.A., et al. Eosinophilic solid and cystic (ESC) renal cell carcinomas harbor TSC mutations: molecular analysis supports an expanding clinicopathologic spectrum. Am J Surg Pathol. 2018;42(9):1166–1181. DOI: 10.1097/PAS.0000000000001111.Akgul M., Cheng L. Immunophenotypic and pathologic heterogeneity of unclassified renal cell carcinoma: a study of 300 cases. Hum Pathol. 2020;102:70–78. DOI: 10.1016/j.humpath.2020.06.007.Akgul M., Cheng L. Immunophenotypic and pathologic heterogeneity of unclassified renal cell carcinoma: a study of 300 cases. Hum Pathol. 2020;102:70–78. DOI: 10.1016/j.humpath.2020.06.007.Argani P., Zhang L., Reuter V.E., et al. RBM10-TFE3 renal cell carcinoma: a potential diagnostic pitfall due to cryptic intrachromosomal Xp11.2 inversion resulting in false-negative TFE3 FISH. Am J Surg Pathol. 2017;41(5):655–662. DOI: 10.1097/PAS.0000000000000835.Argani P., Zhang L., Reuter V.E., et al. RBM10-TFE3 renal cell carcinoma: a potential diagnostic pitfall due to cryptic intrachromosomal Xp11.2 inversion resulting in false-negative TFE3 FISH. Am J Surg Pathol. 2017;41(5):655–662. DOI: 10.1097/PAS.0000000000000835.Argani P., Antonescu C.R., Couturier J., et al. PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21). Am J Surg Pathol. 2002;26(12):1553–1566. DOI: 10.1097/00000478-200212000-00003.Argani P., Antonescu C.R., Couturier J., et al. PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21). Am J Surg Pathol. 2002;26(12):1553–1566. DOI: 10.1097/00000478-200212000-00003.Argani P., Aulmann S., Karanjawala Z., et al. Melanotic Xp11 translocation renal cancers: a distinctive neoplasm with overlapping features of PEComa, carcinoma, and melanoma. Am J Surg Pathol. 2009;33(4):609–619. DOI: 10.1097/PAS.0b013e31818fbdff.Argani P., Aulmann S., Karanjawala Z., et al. Melanotic Xp11 translocation renal cancers: a distinctive neoplasm with overlapping features of PEComa, carcinoma, and melanoma. Am J Surg Pathol. 2009;33(4):609–619. DOI: 10.1097/PAS.0b013e31818fbdff.Argani P., Aulmann S., Illei P.B., et al. A distinctive subset of PEComas harbors TFE3 gene fusions. Am J Surg Pathol. 2010;34(10):1395–1406. DOI: 10.1097/PAS.0b013e3181f17ac0.Argani P., Aulmann S., Illei P.B., et al. A distinctive subset of PEComas harbors TFE3 gene fusions. Am J Surg Pathol. 2010;34(10):1395–1406. DOI: 10.1097/PAS.0b013e3181f17ac0.Argani P., Reuter V.E., Zhang L., et al. TFEB-amplified renal cell carcinomas: an aggressive molecular subset demonstrating variable melanocytic marker expression and morphologic heterogeneity. Am J Surg Pathol. 2016;40(11):1484–1495. DOI: 10.1097/PAS.0000000000000720.Argani P., Reuter V.E., Zhang L., et al. TFEB-amplified renal cell carcinomas: an aggressive molecular subset demonstrating variable melanocytic marker expression and morphologic heterogeneity. Am J Surg Pathol. 2016;40(11):1484–1495. DOI: 10.1097/PAS.0000000000000720.Skala S.L., Xiao H., Udager A.M., et al. Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays. Mod Pathol. 2018;31(1):179–197. DOI: 10.1038/modpathol.2017.99.Skala S.L., Xiao H., Udager A.M., et al. Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays. Mod Pathol. 2018;31(1):179–197. DOI: 10.1038/modpathol.2017.99.Gupta S., Argani P., Jungbluth A.A., et al. TFEB expression profiling in renal cell carcinomas: clinicopathologic correlations. Am J Surg Pathol. 2019;43(11):1445–1461. DOI: 10.1097/PAS.0000000000001307.Gupta S., Argani P., Jungbluth A.A., et al. TFEB expression profiling in renal cell carcinomas: clinicopathologic correlations. Am J Surg Pathol. 2019;43(11):1445–1461. DOI: 10.1097/PAS.0000000000001307.Xia Q.Y., Wang X.T., Fang R., et al. Clinicopathologic and molecular analysis of the TFEB fusion variant reveals new members of TFEB translocation renal cell carcinomas (RCCs): expanding the genomic spectrum. Am J Surg Pathol. 2020;44(4):477–489. DOI: 10.1097/PAS.0000000000001408.Xia Q.Y., Wang X.T., Fang R., et al. Clinicopathologic and molecular analysis of the TFEB fusion variant reveals new members of TFEB translocation renal cell carcinomas (RCCs): expanding the genomic spectrum. Am J Surg Pathol. 2020;44(4):477–489. DOI: 10.1097/PAS.0000000000001408.Caliò A., Harada S., Brunelli M., et al. TFEB rearranged renal cell carcinoma: a clinicopathologic and molecular study of 13 cases. Tumors harboring MALAT1-TFEB, ACTB-TFEB, and the novel NEAT1-TFEB translocations constantly express PDL1. Mod Pathol. 2021;34(4):842–850. DOI: 10.1038/s41379-020-00713-6.Caliò A., Harada S., Brunelli M., et al. TFEB rearranged renal cell carcinoma: a clinicopathologic and molecular study of 13 cases. Tumors harboring MALAT1-TFEB, ACTB-TFEB, and the novel NEAT1-TFEB translocations constantly express PDL1. Mod Pathol. 2021;34(4):842–850. DOI: 10.1038/s41379-020-00713-6.Harrison W.J., Andrici J., Maclean F., et al. Fumarate hydratase-deficient uterine leiomyomas occur in both the syndromic and sporadic settings. Am J Surg Pathol. 2016;40(5):599–607. DOI: 10.1097/PAS.0000000000000573.Harrison W.J., Andrici J., Maclean F., et al. Fumarate hydratase-deficient uterine leiomyomas occur in both the syndromic and sporadic settings. Am J Surg Pathol. 2016;40(5):599–607. DOI: 10.1097/PAS.0000000000000573.Watanabe I.C., Billis A., Guimarães M.S., et al. Renal medullary carcinoma: report of seven cases from Brazil. Mod Pathol. 2007;20(9):914–920. DOI: 10.1038/modpathol.3800934.Watanabe I.C., Billis A., Guimarães M.S., et al. Renal medullary carcinoma: report of seven cases from Brazil. Mod Pathol. 2007;20(9):914–920. DOI: 10.1038/modpathol.3800934.O’Donnell P.H., Jensen A., Posadas E.M., et al. Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy. Nat Rev Urol. 2010;7(2):110–114. DOI: 10.1038/nrurol.2009.255.O’Donnell P.H., Jensen A., Posadas E.M., et al. Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy. Nat Rev Urol. 2010;7(2):110–114. DOI: 10.1038/nrurol.2009.255.Agaimy A. The expanding family of SMARCB1(INI1)-deficient neoplasia: implications of phenotypic, biological, and molecular heterogeneity. Adv Anat Pathol. 2014;21(6):394–410. DOI: 10.1097/PAP.0000000000000038.Agaimy A. The expanding family of SMARCB1(INI1)-deficient neoplasia: implications of phenotypic, biological, and molecular heterogeneity. Adv Anat Pathol. 2014;21(6):394–410. DOI: 10.1097/PAP.0000000000000038.Debelenko L.V., Raimondi S.C., Daw N., et al. Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. Mod Pathol. 2011;24(3):430–442. DOI: 10.1038/modpathol.2010.213.Debelenko L.V., Raimondi S.C., Daw N., et al. Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. Mod Pathol. 2011;24(3):430–442. DOI: 10.1038/modpathol.2010.213.Sugawara E., Togashi Y., Kuroda N., et al. Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method. Cancer. 2012;118(18):4427–4436. DOI: 10.1002/cncr.27391.Sugawara E., Togashi Y., Kuroda N., et al. Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method. Cancer. 2012;118(18):4427–4436. DOI: 10.1002/cncr.27391.Kuroda N., Trpkov K., Gao Y., et al. ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217. Mod Pathol. 2020;33(12):2564–2579. DOI: 10.1038/s41379-020-0578-0.Kuroda N., Trpkov K., Gao Y., et al. ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217. Mod Pathol. 2020;33(12):2564–2579. DOI: 10.1038/s41379-020-0578-0.Pal S.K., Bergerot P., Dizman N., et al. Responses to alectinib in ALK-rearranged papillary renal cell carcinoma. Eur Urol. 2018;74(1):124–128. DOI: 10.1016/j.eururo.2018.03.032.Pal S.K., Bergerot P., Dizman N., et al. Responses to alectinib in ALK-rearranged papillary renal cell carcinoma. Eur Urol. 2018;74(1):124–128. DOI: 10.1016/j.eururo.2018.03.032.Shah R.B., Stohr B.A., Tu Z.J., et al. “Renal cell carcinoma with leiomyomatous stroma” harbor somatic mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): clinicopathologic and molecular characterization of 18 sporadic tumors supports a distinct entity. Am J Surg Pathol. 2020;44(5):571–581. DOI: 10.1097/PAS.0000000000001422.Shah R.B., Stohr B.A., Tu Z.J., et al. “Renal cell carcinoma with leiomyomatous stroma” harbor somatic mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): clinicopathologic and molecular characterization of 18 sporadic tumors supports a distinct entity. Am J Surg Pathol. 2020;44(5):571–581. DOI: 10.1097/PAS.0000000000001422.DiNatale R.G., Gorelick A.N., Makarov V., et al. Putative drivers of aggressiveness in TCEB1-mutant renal cell carcinoma: an emerging entity with variable clinical course. Eur Urol Focus. 2021;7(2):381–389. DOI: 10.1016/j.euf.2019.11.013.DiNatale R.G., Gorelick A.N., Makarov V., et al. Putative drivers of aggressiveness in TCEB1-mutant renal cell carcinoma: an emerging entity with variable clinical course. Eur Urol Focus. 2021;7(2):381–389. DOI: 10.1016/j.euf.2019.11.013.

The authors declare that there are no conflicts of interest present.